Clinical Trial Update: A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating ABT-263 (navitoclax) with erlotinib, ABT-263 with irinotecan, and ABT-263 monotherapy in cancer patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• ABT-263 (navitoclax)
• Camptosar (irinotecan)
• Tarceva (erlotinib)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Solid Tumors | Phase 1 | Status: COMPLETED